This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Ranked Growth Stocks to Buy for March 12th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 12th
Here's Why You Should Add McKesson (MCK) to Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Should Value Investors Buy Hologic (HOLX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.
PerkinElmer (PKI) Boosts Testing Portfolio With New Solutions
by Zacks Equity Research
PerkinElmer's (PKI) introduction of two comprehensive solutions is likely to strengthen its COVID-19 testing portfolio further.
BD (BDX), ImageMover Partner for Rapid Antigen Test Reporting
by Zacks Equity Research
BD (BDX) collaborates with ImageMover to streamline rapid antigen testing results performed on the BD Veritor Plus System.
Integra (IART) Neurosurgery Grows Sequentially Amid Supply Woe
by Zacks Equity Research
Most of Integra's (IART) franchises or products succeed in sustaining the momentum after returning to growth in the third quarter.
AngioDynamics (ANGO) at a 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about NanoKnife platform growth and the recent launch of Auryon Atherectomy.
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
Investor optimism is high on AMN Healthcare (AMN) stock, courtesy of its solid prospects.
Hologic (HOLX) Partners With Gallup on Women's Health Index
by Zacks Equity Research
Hologic (HOLX) is working to develop a global women's health index through Gallup's World Poll to improve quality of life and life expectancy of women worldwide.
BD (BDX) Acquires GSL Solutions for Medication Management
by Zacks Equity Research
This acquisition should improve BD's (BDX) advanced medication management capabilities to further cater to the needs of retail pharmacies including those in outpatient settings.
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, courtesy of its solid prospects.
Here's Why You Should Bet on Select Medical (SEM) Stock Now
by Zacks Equity Research
Select Medical (SEM) has been gaining momentum from consistent rise in top-line growth, strong U.S. footprint and solid cash generating abilities.
Myriad Genetics (MYGN) Collaborates to Advance Oncology Care
by Zacks Equity Research
Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.
Top Ranked Growth Stocks to Buy for March 5th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 5th
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor optimism is high on CONMED (CNMD) stock, courtesy of its solid prospects.
National Vision (EYE) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q4.
Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF
by Zacks Equity Research
Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.
Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription business and Professional Service segments perform impressively in fiscal Q4.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.
HOLX or SMLR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Hologic (HOLX) Boosts Diagnostics Portfolio With New Buyout
by Zacks Equity Research
Hologic (HOLX) strengthens international capabilities and expands diagnostics arm across test menu, customer segments and geography with recent acquisition.
DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses consumable revenue growth in the fourth quarter.
PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.